Claim 1: an antagonist of Human Antibody or Fragment of this adapted or separate that binds specifically to the domain I (sec. With no. 9) st2l ident: Human. Claim 12: The Antibody isolated from claim 1 which comprises a variable region of the heavy chain (VH) comprising a framework derived from sequences of VH - 23 ighv3 Framework (sec. With no ident.158), lghv1: - 24 * 01 (sec. With no. of ident: 148 lghv1 - F * 01) or human (sec. With no. of ident: 149), and a light chain variable region (VL) comprising a framework derived from VL sequences framework of igkv3 - 11 (l6) (sec. With no ident.: 159), lgkv3 01 15 * (L2) (sec. With no. of ident: 150), lgkv1 - 9 * 01 (l8) (sec. With no. 151), lgkv1 ident: 5 * 01 (L12) (sec. With no ident.: 152), lgkv1 - 12 * 01 (L5) (sec. With no. of ident: 153), lgkv1 - 39 * 01 (O12) (sec. With no. of ident: 154), igkv1 - 27 * 01 (A20) (sec. With no. of ident: 155) or igkv1 - 33 * 01 (O18) (sec. With no. of ident: 156) Human. Claim: a 19 polinucle u00f3tido isolated encodes the VH of the sec. With no. of ident: 143, 144, 145, 186, 187, 197, 198, 199, 200, 201, 202, 203, 204, 205, The VL or the sec.With no. of ident: 135, 136, 137, 138, 139, 140, 141, 142, 206, 207, 208 or 209. Claim 22: a method for producing an Antibody of claim 18, which comprises culturing a host cell of claim 21 and the Recovery of the Antibody from the cell.Claim 23: a Pharmaceutical composition comprising an Antibody isolated from claim 1 or a pharmaceutically acceptable Carrier and claim 6.Reivindicación 1: Un antagonista de anticuerpo humano adaptado o separado o fragmento de este que se une, específicamente, al Dominio I (sec. con núm. de ident.: 9) de ST2L humano. Reivindicación 12: El anticuerpo aislado de la reivindicación 1, que comprende una región variable de la cadena pesada (VH) que comprende un marco VH derivado de secuencias marco de IGHV3-23 (sec. con núm. de ident.: 158), lGHV1-24*01 (sec. con núm. de ident.: 148) o lGHV1-f*01 humanas (sec. con núm
